# ENDEAVOR (NCT01568866)

> Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01568866
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: Multiple Myeloma
- Interventions: Carfilzomib; Bortezomib; Dexamethasone
- Enrollment: 929
- Primary outcome: Progression-free Survival

## Indexed commentary on ENDEAVOR so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 post on Bluesky

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=endeavor-nct01568866
